SEC Comment Letter for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686) (TEVA) — Apr 9, 2018
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686)
Date: April 9, 2018 · CIK: 0000818686 · Accession: 0000000000-18-010624
AI Filing Summary & Sentiment
File numbers found in text: 333-224102
Letter
April 9, 2018 Kåre Schultz Chief Executive Officer Teva Pharmaceutical Industries Limited 5 Basel Street P.O. Box 3190 Petach Tikvah, 4951033, Israel Re:Teva Pharmaceutical Industries Limited Registration Statement on Form S-4 Filed April 2, 2018 File No. 333-224102 Dear Mr. Schultz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Ross M. Leff, Esq.
Show Raw Text
April 9, 2018
Kåre Schultz
Chief Executive Officer
Teva Pharmaceutical Industries Limited
5 Basel Street
P.O. Box 3190
Petach Tikvah, 4951033, Israel
Re:Teva Pharmaceutical Industries Limited
Registration Statement on Form S-4
Filed April 2, 2018
File No. 333-224102
Dear Mr. Schultz:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Ross M. Leff, Esq.